/
MNPR
$94.56+$6.88 (+7.85%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$587.4M
7M shares
52-week range
$29.18 – $105.00
86% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.86%
Moderate
Price (6 mo)
Loading chart…
Change+$65.31
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.8M | $2.0M | $4.1M | $6.5M | $7.6M | $5.6M | $13.0M | $9.90B |
| Operating income | −$3.4M | −$4.3M | −$6.5M | −$9.1M | −$10.5M | −$8.8M | −$16.2M | −$16.7M |
| EBITDA | $0 | −$4.2M | $0 | −$9.1M | −$10.5M | −$8.4M | −$15.6M | −$13.7M |
| Net income | −$3.2M | −$4.2M | −$6.3M | −$9.1M | −$10.5M | −$8.4M | −$15.6M | −$13.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.31 | -0.40 | -0.58 | -0.73 | -0.83 | -0.58 | -1.36 | -1.85 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $400000 | $-2.77 | $-5.17–$-1.34 | 9 |
| 2027 | $15M | $-3.51 | $-7.28–$-1.15 | 6 |
| 2028 | $83M | $-1.67 | $-6.07–$1.81 | 6 |
| 2029 | $163M | $1.04 | $0.20–$1.97 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.99
Price
$94.56
Implied downside
-92%
Peer comparison
Monopar Therapeutics Inc. Common Stock
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
www.monopartx.com- Employees
- 22
- IPO / List date
- Dec 19, 2019
- HQ
- WILMETTE, IL
Held by traders on TradeandTell
No one on the platform currently holds MNPR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 11,431 | $746.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-08-13 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded MNPR yet.
